SCHEMBL20729348

SCHEMBL20729348

CC(C)OC(=O)N1CC(=O)Nc2ccc(Cl)cc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.47
SLC6A15 Q9H2J7 1/20 0.41
OXTR P30559 3/20 0.40
ATM Q13315 1/20 0.40
ALDH1A1 P00352 1/20 0.38
CMA1 P23946 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
BRD4 O60885 1/20 0.37
TSHR P16473 1/20 0.37
TP53 P04637 1/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
ABHD6 Q9BV23 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20582194 0.87 SLC6A15 (0.40) AHRSLC6A15OXTRALDH1A1BRD4
SCHEMBL2359709 0.83 CRBN (0.47) AHROXTRATMMEN1KMT2A
SCHEMBL6779500 0.73 CRBN (0.50) AHROXTRATMCMA1MEN1
SCHEMBL5107807 0.73 AHR (0.60) AHRATMCMA1MEN1KMT2A
SCHEMBL18138934 0.72 IDO1 (0.44) ALDH1A1MEN1KMT2APGR
SCHEMBL6540429 0.71 PGR (0.46) MEN1KMT2ABRD4PGR
SCHEMBL2359726 0.70 ESR2 (0.44) AHROXTRMEN1KMT2APSEN1
SCHEMBL7712048 0.70 ESR2 (0.44) AHROXTRMEN1KMT2APSEN1
SCHEMBL18138924 0.70 GHSR (0.39) SLC6A15ALDH1A1TP53
SCHEMBL7915917 0.69 NOTUM (0.55) ABHD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186577-B2 Vasopressin receptor antagonists and products and methods related thereto BLACKTHORN THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20190048013-A1 VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO Neumora Therapeutics, Inc. 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11186577-B2 Vasopressin receptor antagonists and products and methods related thereto AVPR1B, AVPR1A, AVPR2 AHR 1639/4885SLC6A15 498/4885OXTR 8/4885
US-20190048013-A1 VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO AVPR1B, AVPR1A, AVPR2 AHR 1639/4885SLC6A15 498/4885OXTR 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.